• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

57
46
42
36
34

COUNTRY

34
12
12
12

CATEGORIES

  • 120
  • 67
  • 11
  • 9
  • 8
  • 5
  • 4
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

170
203
207
222

PUBLISHED

1
6
19
222

PRODUCT TYPE

138
47
32
3
2

Search "Company Financials: Alkermes, Inc." returned 222 results.

Alkermes, Inc. Company Profile - Business Description, Strategies, SWOT and Financial Analysis Alkermes, Inc. Company Profile - Business Description, Strategies, SWOT and Financial Analysis - Product Thumbnail Image

Alkermes, Inc. Company Profile - Business Description, Strategies, SWOT and Financial Analysis

“Alkermes, Inc. Company Profile” is a comprehensive report on Alkermes, Inc.. The report provides complete information on the operations, organization structure and financial information details of...

October 2014
FROM
Alkermes, Inc. (ALKS) - Financial and Strategic Analysis Review Alkermes, Inc. (ALKS) - Financial and Strategic Analysis Review - Product Thumbnail Image

Alkermes, Inc. (ALKS) - Financial and Strategic Analysis Review

Alkermes, Inc., (Alkermes) is a biotechnology company that develops and manufactures extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such...

July 2010
FROM
Alkermes, Inc. - Product Pipeline Review - Q2 2011 Alkermes, Inc. - Product Pipeline Review - Q2 2011 - Product Thumbnail Image

Alkermes, Inc. - Product Pipeline Review - Q2 2011

Alkermes, Inc. – Product Pipeline Review – Q2 2011 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q2 2011” provides data on the Alkermes, Inc.’s...

July 2011
FROM

Alkermes, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Project Synopsis: Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by...

June 2013
FROM

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

July 2014
FROM
Alkermes, Inc. - Product Pipeline Review - H2 2011 Alkermes, Inc. - Product Pipeline Review - H2 2011 - Product Thumbnail Image

Alkermes, Inc. - Product Pipeline Review - H2 2011

Alkermes, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - H2 2011” provides data on the Alkermes, Inc.’s...

November 2011
FROM
Alkermes, Inc. - Product Pipeline Review - Q4 2010 Alkermes, Inc. - Product Pipeline Review - Q4 2010 - Product Thumbnail Image

Alkermes, Inc. - Product Pipeline Review - Q4 2010

Alkermes, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research...

November 2010
FROM

Alkermes, Inc. - Product Pipeline Review - Q4 2010

Alkermes, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research...

November 2010
FROM
Research Update: Alkermes PLC Rating Raised To 'BB', Outlook Stable On Better-Than-Expected Performance; First-Lien Rating Also Raised Jul 13 Research Update: Alkermes PLC Rating Raised To 'BB', Outlook Stable On Better-Than-Expected Performance; First-Lien Rating Also Raised Jul 13 - Product Thumbnail Image

Research Update: Alkermes PLC Rating Raised To 'BB', Outlook Stable On Better-Than-Expected Performance; First-Lien Rating Also Raised Jul 13

Abstract Alkermes' performance for the fiscal year ended March 31, 2013, exceeded our expectations, with leverage declining to less than 2x, and we expect financial metrics to further improve over...

July 2013
Alkermes Inc. Nov 11 Alkermes Inc. Nov 11 - Product Thumbnail Image

Alkermes Inc. Nov 11

Abstract A track record of successful internal product development; The absence of near-term patent expirations; and Barriers to competitive entry for its injectable drug delivery technology and related...

November 2011
Recovery Report: Alkermes Inc.'s Recovery Rating Profile Jun 11 Recovery Report: Alkermes Inc.'s Recovery Rating Profile Jun 11 - Product Thumbnail Image

Recovery Report: Alkermes Inc.'s Recovery Rating Profile Jun 11

Abstract In conjunction with Waltham, Mass.-based Alkermes Inc.'s acquisition of Elan Drug Technologies, Standard & Poor's Ratings Services assigned preliminary recovery and preliminary issue-level...

June 2011

Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

Recent Biotech Funding, Deals and Partnerships Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years,...

May 2014
FROM
CreditStats: Biotechnology--U.S. Aug 12 CreditStats: Biotechnology--U.S. Aug 12 - Product Thumbnail Image

CreditStats: Biotechnology--U.S. Aug 12

Companies mentioned in this report are: - Amgen Inc. - Biogen Idec Inc. - Celgene Corp. - BioMarin Pharmaceutical Inc. (Unsolicited Ratings) - Gilead Sciences Inc. - Alkermes Inc. Standard...

August 2012

Rating and Forecast Report ALKERMES INC

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. Our three models: Valuation Model, Forecast Model...

May 2015
Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11 Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11 - Product Thumbnail Image

Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, acquired a similar operation from Elan Corp. plc for approximately $1 billion on Sept. 16, 2011, of which $450 million...

October 2011
Research Update: Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11 Research Update: Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11 - Product Thumbnail Image

Research Update: Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, acquired a similar operation from Elan Corp. plc for approximately $1 billion on Sept. 16, 2011, of which $450 million...

October 2011
Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11 Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11 - Product Thumbnail Image

Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, is acquiring a similar operation from Elan Corp. plc for about $1.1 billion, of which $450 million will be funded from...

June 2011
Research Update: Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11 Research Update: Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11 - Product Thumbnail Image

Research Update: Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, is acquiring a similar operation from Elan Corp. plc for about $1.1 billion, of which $450 million will be funded from...

June 2011
Summary: Alkermes Inc. Nov 11 Summary: Alkermes Inc. Nov 11 - Product Thumbnail Image

Summary: Alkermes Inc. Nov 11

Abstract Our speculative-grade rating on Alkermes Inc. reflects a weak business risk profile exhibited by the uncertainty associated with a transformational acquisition, product concentration, dependence...

November 2011

Drug Delivery Series: The Market for Injectable and Implantable Drug Delivery Systems: Volume 2

Drug Delivery Series: The Market for Injectable and Implantable Drug Delivery Systems: Volume 2 The changing climate of injectable/implantable drug delivery system development has been fostered...

October 2001
Loading Indicator

Our Clients

NBC Universal Inc. Samsung Group Ltd. E.ON SE DHL International GmbH University of Cambridge Kone Oyj BP Plc.